In its upcoming report, BioMarin Pharmaceutical (BMRN) is predicted by Wall Street analysts to post quarterly earnings of $0.25 per share, reflecting a decline of 72.8% compared to the same period last year. Revenues are forecasted to be $829.66 million, representing a year-over-year increase of 11%.Over the last 30 days, there has been a downward revision of 2.3% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of ...

BioMarin Pharmaceutical (NASDAQ:BMRN) is one of the 17 biotechnology stocks with more than 50% upside. As of February 12 closing, BioMarin Pharmaceutical (NASDAQ:BMRN) carried a moderately bullish analyst sentiment. Of the 15 analysts covering the stock, 10 assigned Buy ratings and 5 issued Hold ratings. With no Sell rating, the stock has a projected median 1-year price target of $88.29, implying more than 47% upside. UniQure (QURE) Reports Positive Phase I/IIa AMT-191 Data for Fabry Disease, Shows Susta ...

Industry Overview - The biotechnology sector in 2025 faced both challenges and opportunities, remaining on a high-growth trajectory due to clinical and operational breakthroughs, but is expected to encounter significant regulatory, political, and financial uncertainties going forward [1] - A report by Boston Consulting Group titled "Biopharma Trends 2026" indicates a shift in R&D spending towards large populations and real-world applicability, alongside an increase in M&A activity as companies pursue inorganic growth strategies [2] - Cost-optimization measures will be a priority for biopharma companies to achieve target margins, necessitating a rethink of business models and the incorporation of AI in operations to sustain themselves [2] Market Dynamics - Biotechnology stocks exhibit high volatility, presenting both risks and attractive opportunities for investors, with careful selection potentially leading to significant portfolio outperformance [3] - The article explores 17 biotechnology stocks identified as having more than 50% upside potential, emphasizing the need for careful navigation in this competitive and rapidly evolving segment [3] Stock Selection Methodology - The selection process for relevant stocks involved screening U.S.-listed biotechnology companies with market capitalizations above $2 billion and share prices above $5, identifying those with at least 50% upside potential based on TipRanks consensus [5] Company Highlights - **BioMarin Pharmaceutical (NASDAQ:BMRN)**: - Holds a moderately bullish analyst sentiment with a projected median 1-year price target of $88.29, implying over 47% upside potential [8] - The company develops targeted therapies for life-threatening medical conditions and rare genetic diseases, with several drugs in the development stage [10] - **Apogee Therapeutics (NASDAQ:APGE)**: - Analysts maintain a Buy rating with a price target of $95, indicating potential upside of over 37% despite recent selloff viewed as an overreaction [11][12] - The company is developing novel biologics for inflammatory and immune diseases, with a pipeline that includes multiple candidates in various clinical trial stages [15] - **Arcellx Incorporated (NASDAQ:ACLX)**: - Analysts have mixed ratings, with one maintaining a Buy rating and a price target of $127, suggesting an upside potential of 85% [18] - The company focuses on advanced immunotherapies for cancer patients, leveraging proprietary technology to develop effective treatments targeting various malignancies [20]

Group 1 - BioMarin Pharmaceutical (NASDAQ:BMRN) is identified as a promising large-cap stock under $100 with significant upside potential, with price targets revised upwards by analysts [1][3] - Canaccord Genuity analyst Whitney Ijem upgraded her rating from Hold to Buy and increased the price target from $84 to $98, indicating a potential upside of nearly 75% [1][2] - Truist Securities analyst Joon Lee also raised his price target from $80 to $100, suggesting a potential upside of approximately 78% while maintaining a Buy rating [3] Group 2 - Both analysts attribute their positive outlook to BioMarin's potential acquisition of Amicus Therapeutics, which is expected to be finalized in the second quarter of 2026 [4] - The acquisition is seen as strategically aligned with BioMarin's focus on rare diseases and its existing drug portfolio, particularly highlighting Amicus's approved drugs, Galafold and PomOp [4] - The deal is anticipated to be accretive within 12 months, further enhancing BioMarin's growth prospects [4] Group 3 - BioMarin specializes in developing and commercializing targeted therapies for life-threatening medical conditions and rare genetic diseases, with key products including VIMIZIM, VOXZOGO, NAGLAZYME, and ALDURAZYME [5] - The company operates in over 70 countries and has a robust pipeline of drugs in various stages of development [5]

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the 10 Cheap Stocks with Huge Upside Potential. On January 20, Canaccord Genuity raised BioMarin Pharmaceutical Inc.’s (NASDAQ:BMRN) price target from $84 to $98, implying 74.4% upside from the current share price. On January 13, Wedbush analyst Yun Zhong reaffirmed his Buy rating on the stock while maintaining a price target of $94. Yun Zhong’s Buy rating is based on several factors that reinforce the company’s ability to deliver sustained long-term gro ...

44th Annual J.P. Morgan Healthcare Conference Alexander Hardy Chief Executive Officer Greg Friberg Chief R&D Officer BioMarin Pharmaceutical Inc. January 12, 2026 These risks and uncertainties include, without limitations, risks relating to the completion of BioMarin's normal quarterly and annual accounting and financial statement closing procedures for the quarter and the year ended December 31, 2025; the timing of orders for commercial products; BioMarin's ability to meet product demand; risks and uncerta ...

Core Viewpoint - BioMarin Pharmaceutical Inc. is considered a cheap healthcare stock with potential for investment heading into 2026, despite recent downgrades in price targets by analysts [1][3]. Group 1: Analyst Ratings and Price Targets - Leerink reduced the price target on BioMarin to $60 from $82 and downgraded it to Market Perform from Outperform on December 3 [1]. - Bernstein also lowered the price target to $88 from $95, maintaining a Market Perform rating, noting that the company's quarterly performance met revenue expectations but missed EPS targets [3]. - The majority of analysts assign a 'Buy' or equivalent rating to BioMarin, with target prices ranging from $55 to $122, and a median price target of $91 suggesting an upside potential of about 70% [4]. Group 2: Company Actions and Market Position - New leadership's actions, including workforce cuts and discontinuation of the Roctavian program, are seen as strengthening BioMarin's long-term position [2]. - Rising competitive pressure in the achondroplasia market and a significant gap in the company's pipeline may necessitate mergers and acquisitions, creating uncertainty about the effectiveness of current measures to boost stock performance [2]. Group 3: Company Overview - BioMarin Pharmaceutical Inc. is a California-based biotechnology company focused on developing and marketing therapies for serious rare diseases, with core offerings including VIMIZIM, VOXZOGO, NAGLAZYME, and PALYNZIQ [4].

Group 1 - BioMarin Pharmaceutical Inc. reported fiscal Q3 2025 total revenues of $776 million, reflecting a 4% growth year-over-year, driven by strong performance in VOXZOGO and PALYNZIQ due to new patient initiations [1] - Year-to-date total revenues increased by 11% year-over-year, with PALYNZIQ and VOXZOGO showing over 20% revenue growth [2] - J.P. Morgan analyst Jessica Fye reiterated a Buy rating on BioMarin, indicating that the company's underlying business is undervalued [2] Group 2 - The company has a strong growth potential and a solid market position, supported by considerable capital for business development and a robust product pipeline [3] - BioMarin develops therapies for serious and life-threatening medical conditions and rare diseases, with key products in its pipeline including Valoctocogene roxaparvovec, Vosoritide, and BMN 307 [3]

Core Insights - BioMarin Pharmaceutical Inc. is identified as a stock with exponential growth potential heading into 2026, driven by strong performance in its Enzyme Therapies and Skeletal Conditions business units [1] - The company reported a 4% increase in total revenues for Q3 2025, amounting to $776 million, supported by over 20% revenue growth from PALYNZIQ and VOXZOGO [3] Financial Performance - Total revenues for Q3 2025 reached $776 million, reflecting a 4% increase compared to Q3 2024 [3] - Revenue growth was significantly attributed to new patient initiations for VOXZOGO and PALYNZIQ across all regions, indicating a robust demand for these therapies [3] Strategic Focus - The company is concentrating on its Enzyme Therapies and Skeletal Conditions as key components of its growth strategy, while also exploring new business development opportunities [2] - BioMarin is considering divesting ROCTAVIAN to streamline its portfolio and focus on strategic priorities [2]

Core Insights - BioMarin Pharmaceutical Inc reported weaker-than-expected earnings for Q3, with earnings of $0.12 per share, missing the consensus estimate of $0.37 per share, and quarterly sales of $776.133 million, below the expected $780.629 million [1] Financial Performance - The company lowered its FY2025 adjusted EPS guidance from $4.40-$4.55 to $3.50-$3.60, while raising its sales guidance from $3.125 billion-$3.200 billion to $3.150 billion-$3.200 billion [2] - The CEO highlighted over 20% revenue growth from PALYNZIQ and VOXZOGO as key contributors to the business units [2] Stock Performance - Following the earnings announcement, BioMarin shares gained 4.3% to $54.95 [3] Analyst Ratings and Price Targets - Morgan Stanley maintained an Overweight rating but lowered the price target from $104 to $98 [5] - HC Wainwright & Co. maintained a Neutral rating and cut the price target from $60 to $55 [5] - Barclays also maintained an Overweight rating while lowering the price target from $86 to $80 [5]